Aeterna Zentaris (NASDAQ:AEZS) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Up 0.8 %

Shares of AEZS stock opened at $1.97 on Monday. The company has a 50 day moving average of $1.97 and a 200-day moving average of $1.89. Aeterna Zentaris has a 12-month low of $1.36 and a 12-month high of $3.38. The firm has a market cap of $9.57 million, a P/E ratio of -0.58 and a beta of 1.57.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings data on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.19). The business had revenue of $0.12 million during the quarter. Aeterna Zentaris had a negative net margin of 368.01% and a negative return on equity of 63.20%.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.